about
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools.Complete response after rechallenge with trabectedin in a patient with previously responding high-grade undifferentiated sarcoma.A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy.5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.Nutritional management of older adults with gastrointestinal cancers: An International Society of Geriatric Oncology (SIOG) review paper.Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life NomogramAssessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trialBenefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept studyEarly tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord OvestSecond-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world studyDPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patientsPhase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trialA validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' studyItalian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer
P50
Q30855372-5548BE61-7727-49AA-A396-432E342EE262Q38599120-89A56C1F-B58F-4EE3-9C18-7E51C2F67E52Q39061328-DF4DA7E1-A556-4033-B74A-276F5C4BF7B4Q40351383-0D3ACF49-68C6-4877-85C5-DFB9976329DCQ41008543-E7D23EAB-4F06-4F8F-A36C-CD83F9D0EEF0Q46040601-58F7F8E8-03BC-4194-893B-82C3B02C428AQ46616107-E6854831-6836-4F50-8376-55427F9A06E2Q47915753-86A1E744-130A-4294-93A8-BAE0A1627B5CQ48507405-9729B843-F594-4D1B-B7D3-EC8DD19DA3CDQ49959389-E82190F2-BDCA-4DB3-A3B7-E695B70F9D03Q50084785-DFD5B9DC-0026-47E5-A060-7F9DF5CCC434Q52682270-EC3C307C-5E3D-4FEF-AB2A-93A63787373BQ61054483-C0A38172-69C9-4CD4-AED9-374C0304744CQ64100971-E8BF3A6F-6497-475C-8B90-ED550564E51DQ64114213-9E715779-E38D-4E52-81F3-D74888F85B7BQ86824138-370DFF7C-5A85-4A9A-83D8-27DCEF417F65Q90520295-35647893-8212-4172-B813-1841849D32B3Q91361694-58C9FC9B-12B8-448E-AB0A-47B1563C35F1Q91422596-C9B346F9-30DD-4751-93FA-1DFB25DF3D6EQ92079267-C0AD2624-B782-4B94-81FD-CF5CE901960EQ93164221-C8C2CD7C-1E7C-4684-8192-E918D123CFA9
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Samantha Di Donato
@en
Samantha Di Donato
@nl
type
label
Samantha Di Donato
@en
Samantha Di Donato
@nl
prefLabel
Samantha Di Donato
@en
Samantha Di Donato
@nl
P31
P496
0000-0001-8436-7042